ClinicalTrials.Veeva

Menu

Evaluation of the Safety and Tolerability of a Higher Potency Dose of an Investigational Vaccine Among Adults 50 Years of Age and Older (V211-009)

Merck Sharp & Dohme (MSD) logo

Merck Sharp & Dohme (MSD)

Status and phase

Completed
Phase 3

Conditions

Healthy

Treatments

Biological: Comparator: Varicella Zoster Virus Vaccine

Study type

Interventional

Funder types

Industry

Identifiers

NCT00092417
V211-009
2004_075

Details and patient eligibility

About

This study compared the safety and tolerability profile of a higher potency investigational vaccine to that of the investigational vaccine at a lower potency dose.

Enrollment

695 patients

Sex

All

Ages

50+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  • Healthy individuals 50 years of age or older with a history of chickenpox who have not had herpes zoster

Exclusion Criteria :

  • Preexisting conditions that might affect vaccine safety such as conditions that inhibit an immune response

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

695 participants in 2 patient groups

1
Experimental group
Description:
Higher Potency Dose
Treatment:
Biological: Comparator: Varicella Zoster Virus Vaccine
Biological: Comparator: Varicella Zoster Virus Vaccine
2
Experimental group
Description:
Lower Potency Dose
Treatment:
Biological: Comparator: Varicella Zoster Virus Vaccine
Biological: Comparator: Varicella Zoster Virus Vaccine

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems